Robert E. Martell
Net Worth
Last updated:
What is Robert E. Martell net worth?
The estimated net worth of Dr. Robert E. Martell is at least $3,880,136 as of 23 Jan 2019. He owns shares worth $37,534 as insider, has earned $5,902 from insider trading and has received compensation worth at least $3,836,700 in Curis, Inc..
What is the salary of Robert E. Martell?
Dr. Robert E. Martell salary is $639,450 per year as Head of R&D in Curis, Inc..
How old is Robert E. Martell?
Dr. Robert E. Martell is 62 years old, born in 1963.
What stocks does Robert E. Martell currently own?
As insider, Dr. Robert E. Martell owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Curis, Inc. (CRIS) | Head of R&D | 23,027 | $1.63 | $37,534 |
What does Curis, Inc. do?
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.
Robert E. Martell insider trading
Curis, Inc.
Dr. Robert E. Martell has made only one insider trade in 2019, according to the Form 4 filled with the SEC. He sold 5,500 units of CRIS stock worth $5,902 on 23 Jan 2019.
As of 23 Jan 2019 he still owns at least 23,027 units of CRIS stock.
Curis key executives
Curis, Inc. executives and other stock owners filed with the SEC:
- Dr. Robert E. Martell (62) Head of R&D
- Mr. James E. Dentzer (58) Pres, Chief Executive Officer & Director
- Mr. William E. Steinkrauss (39) Chief Financial Officer